Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artesunate/amodiaquine - Drugs for Neglected Diseases Initiative Foundation/Sanofi

Drug Profile

Artesunate/amodiaquine - Drugs for Neglected Diseases Initiative Foundation/Sanofi

Alternative Names: Amodiaquine/artesunate; Artesunate 200mg/amodiaquine 270mg; Artesunate Amodiaquine Winthrop; AS/AQ; ASAQ; ASAQ Winthrop; Coarsucam

Latest Information Update: 08 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; sanofi-aventis
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class 3-ring heterocyclic compounds; Aminoquinolines; Antimalarials; Artemisinins; Diethylamines; Herbal medicines; Small molecules; Succinates
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 08 Feb 2019 Chemical structure information added
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malaria(In adolescents, In children, In the elderly, In adults) in France (PO, Tablet)
  • 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malaria(In adolescents, In children, In the elderly, In adults) in Mali (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top